Note From the Editors
The pace of impact through digital health in 2021 is off to a rapid start be it the number of transactions, the numerous legislative proposals and actions, or the focused attention of enforcement bodies. Given the accelerated pace of tech-enabled methods, such as telehealth or product development through streamlined digital tools and decentralized clinical trials, not to mention AI and big data s impact on diagnostic and research capacity, the policy and regulatory spotlight on digital health will no doubt be bright throughout this year. In the Industry Insights contribution for this issue, several of our digital health experts briefly summarize the focused attention of U.S. enforcement agencies on telehealth given significantly increased reimbursement trends in the area.
Note From the Editors
The pace of impact through digital health in 2021 is off to a
rapid start be it the number of transactions, the numerous
legislative proposals and actions, or the focused attention of
enforcement bodies. Given the accelerated pace of tech-enabled
methods, such as telehealth or product development through
streamlined digital tools and decentralized clinical trials, not to
mention AI and big data s impact on diagnostic and research
capacity, the policy and regulatory spotlight on digital health
will no doubt be bright throughout this year. In the Industry
Insights contribution for this issue, several of our digital
health experts briefly summarize the focused attention of U.S.
Bharat Biotech Covaxin shows 78 percent overall interim efficacy, 100 percent efficacy against severe Covid medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.
Apr 21, 2021
Safety and Efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication. Based on the achievement of the success criteria, placebo recipients have now become eligible to receive two doses of COVAXIN®.
The Phase 3 study enrolled 25,800 participants between 18-98 years of age, including 10% over the age of 60, with analysis conducted 14 days post 2
nd dose. COVAXIN® was developed with seed strains received from the National Institute of Virology, and the phase 3 clinical trial was co-funded by the Indian Council of Medical Research, making it a true public, private partnership towards public health.